Protosappanin A (PTA), an immune agent, is a major biphenyl compound isolated from Caesalpinia sappan L that inhibits the JAK2/STAT3-dependent inflammatory pathway by down-regulating the phosphorylation of JAK2 and STAT3.
|Solubility (25°C)||DMSO ≥ 200 mg/mL|
|Storage||4°C protect from light dry|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related JAK Products|
Londamocitinib is a potent and selective JAK1 inhibitor with anti-inflammatory activity.
SJ1008030 TFA is a JAK2 PROTAC which selectively degrades JAK2.
DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand.
STAT3-IN-18 is a platinum (IV) complex with an axial ligand derived from sandalwood.
JAK-IN-28 is a JAK inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.